Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Fig. 3

Changes of HBV virologic markers from baseline during treatment with Canocapavir or placebo. AC Hepatitis B virus (HBV) DNA, DF HBV pregenomic RNA (pgRNA), G hepatitis B surface antigen (HBsAg), H hepatitis e surface antigen (HBeAg), I hepatitis B core-related antigen (HBcrAg)

Back to article page